Diverse monoclonal antibodies against the CA 19‐9 antigen show variation in binding specificity with consequences for clinical interpretation
暂无分享,去创建一个
[1] R. Molina,et al. CA 19–9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer , 2012, Tumor Biology.
[2] P. Andrews,et al. Identification of blood‐protein carriers of the CA 19‐9 antigen and characterization of prevalence in pancreatic diseases , 2011, Proteomics.
[3] D. Chan,et al. Aberrant glycosylation associated with enzymes as cancer biomarkers , 2011, Clinical Proteomics.
[4] X. Chen,et al. Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. , 2011, Cancer research.
[5] David F. Smith,et al. Shotgun Glycomics: A Microarray Strategy for Functional Glycomics , 2010, Nature Methods.
[6] B. Haab,et al. High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays. , 2011, Methods in molecular biology.
[7] C. Sato,et al. Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells. , 2010, Glycobiology.
[8] Edward Suh,et al. A motif-based analysis of glycan array data to determine the specificities of glycan-binding proteins. , 2010, Glycobiology.
[9] U. Mansmann,et al. Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer , 2010, Clinical Cancer Research.
[10] M. Farnell,et al. Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma , 2009, Journal of Gastrointestinal Surgery.
[11] M. Hollingsworth,et al. The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-Lectin Sandwich Arrays* , 2009, Molecular & Cellular Proteomics.
[12] B. Haab,et al. Microarrays in glycoproteomics research. , 2009, Clinics in laboratory medicine.
[13] W. Scheithauer,et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. , 2008, The Lancet. Oncology.
[14] R. Kuick,et al. Low‐volume, high‐throughput sandwich immunoassays for profiling plasma proteins in mice: Identification of early‐stage systemic inflammation in a mouse model of intestinal cancer , 2007, Molecular oncology.
[15] T. Roach,et al. High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. , 2007, Glycobiology.
[16] A. Siriwardena,et al. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] D. Simeone,et al. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. , 2007, Journal of proteome research.
[18] W. Hancock,et al. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. , 2006, Clinical chemistry.
[19] Chi-Huey Wong,et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] A. Varki,et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Alper. Turning Sweet on Cancer , 2003, Science.
[22] N. Willich,et al. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. , 2003, Anticancer research.
[23] J. Alper. Glycobiology. Turning sweet on cancer. , 2003, Science.
[24] D. Couper,et al. Distribution of Lewis (FUT3) genotype and allele: frequencies in a biethnic United States population , 2002, Annals of Hematology.
[25] Maureen E. Taylor,et al. Glycan arrays for functional glycomics , 2002, Genome Biology.
[26] Y. Malykh,et al. N-Glycolylneuraminic acid in human tumours. , 2001, Biochimie.
[27] J. Dennis,et al. Glycoprotein glycosylation and cancer progression. , 1999, Biochimica et biophysica acta.
[28] Carolyn R. Bertozzi,et al. Essentials of Glycobiology , 1999 .
[29] S. Hirohashi,et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. , 1998, Cancer research.
[30] M. Costache,et al. Significance of Individual Point Mutations, T202C and C314T, in the Human Lewis (FUT3) Gene for Expression of Lewis Antigens by the Human α(1,3/1,4)-Fucosyltransferase, Fuc-TIII* , 1997, The Journal of Biological Chemistry.
[31] J. Furuse,et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. , 1997, Hepato-gastroenterology.
[32] T. Ørntoft,et al. Influence of Lewis α1-3/4-L-Fucosyltransferase (FUT3) Gene Mutations on Enzyme Activity, Erythrocyte Phenotyping, and Circulating Tumor Marker Sialyl-Lewis a Levels* , 1996, The Journal of Biological Chemistry.
[33] M. Heikinheimo,et al. Tumor Markers CA 125 and CA 19–9 in Cord Blood and During Infancy: Developmental Changes and Use in Pediatric Germ Cell Tumors , 1995, Pediatric Research.
[34] S. Kawa,et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. , 1991, British Journal of Cancer.
[35] M. Prat,et al. Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells. , 1990, Gastroenterology.
[36] Henrik Clausen,et al. Molecular genetic basis of the histo-blood group ABO system , 1990, Nature.
[37] M. Tempero,et al. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. , 1988, Cancer research.
[38] M. Tempero,et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. , 1987, Cancer research.
[39] W. Schmiegel,et al. Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. , 1986, Cancer research.
[40] H. Koprowski,et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. , 1983, Cancer research.